Could a Court Ruling Upend Medicare Advantage Star Ratings?

Why It Matters

Star Ratings drive tens to hundreds of millions in Medicare Advantage revenue, so any change to their methodology can reshape plan profitability and market dynamics. The ruling challenges CMS’s authority and could trigger costly, slower rulemaking processes across the program.

Key Takeaways

• Clover's rating downgrade cost about $120 million in 2026 payments
• Court ruled CMS exceeded authority on ten Star measure data sources
• CMS may need formal rulemaking for future measure specification changes
• Potential broader impact could reshape Medicare Advantage payment incentives

Pulse Analysis

Medicare Advantage’s Star Ratings have become a pivotal revenue lever, translating quality scores into bonus payments, higher rebate percentages, and marketing advantages. A half‑star swing can mean tens of millions of dollars, as Clover Health’s $120 million loss illustrates. The ratings are built on three statutory data streams—HEDIS, HOS, and CAHPS—yet CMS has historically supplemented these with technical guidance to keep pace with clinical advances. The recent court decision spotlights the tension between statutory constraints and the agency’s need for flexibility, raising questions about the durability of the current bonus structure.

The ruling hinges on two legal findings. First, the judge concluded that ten of Clover’s challenged measures relied on data sources not expressly listed in the Medicare statute, meaning CMS exceeded its authority. Second, the court held that CMS’s practice of updating measure specifications via sub‑regulatory guidance effectively creates substantive legal standards, which under the Administrative Procedure Act require formal notice‑and‑comment rulemaking. If upheld, CMS may have to submit detailed rule proposals for any future specification tweaks, slowing the rollout of new quality metrics and potentially increasing compliance costs for health plans and vendors.

Beyond the immediate case, the decision arrives in a post‑Chevron era where courts are less deferential to agency interpretations. Legal scholars see Clover as a bellwether for how health‑care regulators will be scrutinized when they rely on technical guidance rather than formal rulemaking. Plans, providers, and technology firms should monitor the appellate outcome, possible congressional interventions, and CMS’s internal assessments of data‑source eligibility. Preparing for more rigorous rulemaking processes now could mitigate disruption and preserve competitive positioning in an environment where Star Ratings remain a cornerstone of Medicare Advantage profitability.